Centrally acting antihypertensives and alpha-blockers in people at risk of falls: therapeutic dilemmas—a clinical review

T. J. Welsh, A. Mitchell

Research output: Contribution to journalArticlepeer-review

1 Citation (SciVal)

Abstract

Purpose: To summarise the evidence for deprescribing alpha-blockers and centrally acting antihypertensives in older people at risk of falls and to assist clinicians in deciding how to safely de-prescribe these agents. Findings: Alpha-blockers and centrally acting antihypertensives are no longer recommended for the treatment of hypertension unless all other agents are contraindicated or not tolerated. Multiple tools identify these agents as potentially inappropriate and recommend deprescribing. A number of protocols have been developed to safely guide deprescribing. Message: Safer antihypertensives are available that are associated with less adverse effects. Decision aids such as STOPPFalls can assist de-prescribing.

Original languageEnglish
Pages (from-to)675-682
Number of pages8
JournalEuropean Geriatric Medicine
Volume14
Issue number4
Early online date12 Jul 2023
DOIs
Publication statusPublished - 31 Aug 2023

Bibliographical note

Funding: No funding was received for conducting this study.

Keywords

  • Deprescribing
  • Falls
  • Geriatric
  • Hypertension

ASJC Scopus subject areas

  • Gerontology
  • Geriatrics and Gerontology

Fingerprint

Dive into the research topics of 'Centrally acting antihypertensives and alpha-blockers in people at risk of falls: therapeutic dilemmas—a clinical review'. Together they form a unique fingerprint.

Cite this